A Case of Successfully Treated Severe Heart Failure due to Cyclophosphamide Induced Cardiomyopathy / 임상소아혈액종양
Clinical Pediatric Hematology-Oncology
;
: 71-75, 2018.
Article
in English
| WPRIM
| ID: wpr-714194
ABSTRACT
Cyclophosphamide-induced cardiotoxicity is an uncommon complication especially in patients who have never undergone mediastinal irradiation or cardiotoxic chemotherapy and do not have underlying cardiac diseases. Here, we describe the case of a 19-year-old female with chronic myeloid leukemia. She was previously treated with oral tyrosine kinase inhibitors and developed cardiomyopathy after receiving infusion of 60 mg/kg intravenous cyclophosphamide for two days with a conditioning regimen for allogenic hematopoietic stem cell transplantation. Severe thickening of the left ventricle and reduced ejection fraction without triggering agents were characteristic for cyclophosphamide-induced cardiomyopathy. Her NT-pro BNP and troponin T concentrations surged to >70,000 pg/mL (0=130 pg/mL) and 2,031 pg/mL (0-14 pg/mL), respectively, during the course of the therapy and multiple organ failure seemed imminent evidenced by unresponsive decline in blood pressure. However, with close monitoring and persistent conservative management which consisted of intravenous hydration, continuous hemodialysis, and mechanical ventilation, her condition recovered.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Respiration, Artificial
/
Blood Pressure
/
Protein-Tyrosine Kinases
/
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
/
Renal Dialysis
/
Hematopoietic Stem Cell Transplantation
/
Troponin T
/
Cyclophosphamide
/
Drug Therapy
/
Cardiotoxicity
Limits:
Female
/
Humans
Language:
English
Journal:
Clinical Pediatric Hematology-Oncology
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS